Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jessica Buijs-Gladdines"'
Autor:
Irene Homminga, Maartje J. Vuerhard, Anton W. Langerak, Jessica Buijs-Gladdines, Rob Pieters, Jules P.P. Meijerink
Publikováno v:
Haematologica, Vol 97, Iss 2 (2012)
Translocation of the LYL1 oncogene are rare in T-cell acute lymphoblastic leukemia, whereas the homologous TAL1 gene is rearranged in approximately 20% of patients. Previous gene-expression studies have identified an immature T-cell acute lymphoblast
Externí odkaz:
https://doaj.org/article/970b50e9b4e94bf891b031b4249c09c8
Autor:
Jordy C.G. Van Der Zwet, Willem K. Smits, Jessica Buijs-Gladdines, Rob Pieters, Jules P.P. Meijerink
Publikováno v:
HemaSphere, Vol 5, Iss 1, p e513 (2021)
The glucocorticoid receptor NR3C1 is essential for steroid-induced apoptosis, and deletions of this gene have been recurrently identified at disease relapse for acute lymphoblastic leukemia (ALL) patients. Here, we demonstrate that recurrent NR3C1 in
Autor:
Kirsten Canté-Barrett, J. van der Zwet, Rob Pieters, Willem K. Smits, G.J.R. Zaman, R.C. Buijsman, Joost C.M. Uitdehaag, Jessica Buijs-Gladdines, Jules P.P. Meijerink, J.A.P. Spijkers-Hagelstein
Publikováno v:
Leukemia, 30(9), 1832-1843. Nature Publishing Group
Leukemia
Leukemia
We identified mutations in the IL7Ra gene or in genes encoding the downstream signaling molecules JAK1, JAK3, STAT5B, N-RAS, K-RAS, NF1, AKT and PTEN in 49% of patients with pediatric T-cell acute lymphoblastic leukemia (T-ALL). Strikingly, these mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25d4232f2d8caf2d774fe71bff1af6eb
https://pure.eur.nl/en/publications/7fda49cb-bdc4-4d56-af82-3d8e5d680424
https://pure.eur.nl/en/publications/7fda49cb-bdc4-4d56-af82-3d8e5d680424
Autor:
Willem A. Kamps, Renee X. de Menezes, Jessica Buijs-Gladdines, William E. Evans, Gritta Janka-Schaub, Meyling Cheok, Peter J. van der Spek, Rob Pieters, Susan T C J M Peters, H. Berna Beverloo, Laura J. C. M. van Zutven, Marjon van Slegtenhorst, Martin A. Horstmann, Gaby Escherich, Monique L. den Boer
Publikováno v:
Lancet Oncology, 10, 125-134. Lancet Publishing Group
Lancet Oncology, 10(2), 125-134. ELSEVIER SCIENCE INC
Lancet Oncology, 10(2), 125-134. ELSEVIER SCIENCE INC
Summary Background Genetic subtypes of acute lymphoblastic leukaemia (ALL) are used to determine risk and treatment in children. 25% of precursor B-ALL cases are genetically unclassified and have intermediate prognosis. We aimed to use a genome-wide
Autor:
Rob Pieters, Jessica Buijs-Gladdines, H B Beverloo, E. R. Van Wering, P Van Vlierberghe, Martin A. Horstmann, Jules P.P. Meijerink
Publikováno v:
Leukemia, 22(7), 1434-1437. Nature Publishing Group
Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia
Autor:
A. Olivier Gevaert, A. Thomas Look, Edwin Sonneveld, Johan J. de Rooi, Linda Zuurbier, Yunlei Li, Willem K. Smits, Martin A. Horstmann, Kirsten Canté-Barrett, Charles G. Mullighan, Jessica Buijs-Gladdines, Jules P.P. Meijerink, Alejandro Gutierrez, Rob Pieters
Publikováno v:
Haematologica, 99(1). Ferrata Storti Foundation
Three distinct immature T-cell acute lymphoblastic leukemia entities have been described including cases that express an early T-cell precursor immunophenotype or expression profile, immature MEF2C-dysregulated T-cell acute lymphoblastic leukemia clu
Autor:
Rob Pieters, Martin A. Horstmann, Jessica Buijs-Gladdines, Edwin Sonneveld, Anjo J.P. Veerman, Maartje Vuerhard, Clarissa Kooi, Linda Zuurbier, Valerie S. Calvert, Willem A. Kamps, Willem K. Smits, Emanuel F. Petricoin, Jules P.P. Meijerink
Publikováno v:
Haematologica, 97(9), 1405-1413. FERRATA STORTI FOUNDATION
Haematologica, 97(9), 1405-1413. Ferrata Storti Foundation
Zuurbier, L, Petricoin, E F, Vuerhard, M J, Calvert, V, Kooi, C, Buijs-Gladdines, J G C A, Smits, W K, Sonneveld, E, Veerman, A J P, Kamps, W A, Horstmann, M, Pieters, R & Meijerink, J P P 2012, ' The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia ', Haematologica, vol. 97, no. 9, pp. 1405-1413 . https://doi.org/10.3324/haematol.2011.059030
Haematologica, 97(9), 1405-1413. Ferrata Storti Foundation
Zuurbier, L, Petricoin, E F, Vuerhard, M J, Calvert, V, Kooi, C, Buijs-Gladdines, J G C A, Smits, W K, Sonneveld, E, Veerman, A J P, Kamps, W A, Horstmann, M, Pieters, R & Meijerink, J P P 2012, ' The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia ', Haematologica, vol. 97, no. 9, pp. 1405-1413 . https://doi.org/10.3324/haematol.2011.059030
BackgroundPI3K/AKT pathway mutations are found in T-cell acute lymphoblastic leukemia, but their overall impact and associations with other genetic aberrations is unknown. PTEN mutations have been proposed as secondary mutations that follow NOTCH1-ac
Autor:
Rogier C. Buijsman, Rob Pieters, J.A.P. Spijkers-Hagelstein, Jules P.P. Meijerink, Jessica Buijs-Gladdines, Kirsten Canté-Barrett, Guido J.R. Zaman, Wilco K Smits
Publikováno v:
Blood. 126:445-445
Background: Pediatric T-cell acute lymphoblastic leukemia patients frequently harbor mutations in IL7Ra or downstream molecules encoded by JAK1, JAK3, N-RAS, K-RAS, NF1, AKT, and PTEN. These mutated signaling molecules can contribute to leukemia by d
Autor:
Rob Pieters, Peter Vandenberghe, Tim Lammens, Kirsten Canté-Barrett, Jules P.P. Meijerink, Erik Splinter, Anne Uyttebroeck, Wilco K Smits, Jessica Buijs-Gladdines, Eric Vroegindeweij, Max van Min, Pieter Van Vlierberghe
Publikováno v:
Blood. 126:1409-1409
Background: T-cell acute lymphoblastic leukemia is characterized by clonal and mutual exclusive chromosomal rearrangements that recurrently activate TAL1, LMO2, TLX1, NKX2-1, TLX3, HOXA or MEF2C oncogenes. Most of these translocations or chromosomal
Autor:
Guido J.R. Zaman, Wilco K Smits, Rob Pieters, Kirsten Canté-Barrett, Rogier C. Buijsman, Jessica Buijs-Gladdines, Joost C.M. Uitdehaag, Jules P.P. Meijerink
Publikováno v:
Blood. 126:869-869
Background: Many pediatric T-cell acute lymphoblastic leukemia patients harbor mutations in IL7Ra or downstream molecules encoded by JAK1, JAK3, N-RAS, K-RAS, NF1, AKT, and PTEN. These mutated signaling molecules can contribute to leukemia by disturb